Literature DB >> 24441745

A small molecule, MTBT, prevents cancer cell growth by activating p38 MAPK.

Yan Li1, Xuelian Zhang, Jing Zhang, Yongzhen Li, Wei Liu, Zhen Wang, Yanchang Wang, Shuyi Si.   

Abstract

Cancer is a disease of unscheduled cell division and many anticancer drugs target the cell cycle to inhibit the proliferation of cancer cells. We conducted a screen for new anticancer drugs that induce cell cycle arrest using a small compound library. From this screen, we identified 2-(3-methyl-thiophen-2-yl)-4-(3,4-dioxybenzene) thiazole (MTBT), which causes accumulation of cancer cells with 4N DNA content and inhibits colony formation of several cancer cell lines. We further showed that the treatment of cancer cells with this compound for a longer time period leads to apoptosis, as indicated by the presence of cells with a sub-G1 peak and the appearance apoptotic markers. The increased phosphorylation of serine 10 on histone H3 in MTBT-treated cancer cells suggests cell cycle arrest in the M-phase. Strikingly, MTBT-induced cell cycle arrest and enhanced H3 (Ser10) phosphorylation are abrogated by the pretreatment with SB203580, a specific inhibitor of mitogen-activated protein kinase p38. Moreover, treatment of cancer cells with MTBT induces the phosphorylation of p38, indicative of p38 activation. Together, we have identified a new compound that inhibits cancer cell proliferation, which is likely a consequence of p38 activation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24441745      PMCID: PMC4091034          DOI: 10.1097/CAD.0000000000000074

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  34 in total

1.  Role of the p38 MAPK pathway in cisplatin-based therapy.

Authors:  Javier Hernández Losa; Carlos Parada Cobo; Juan Guinea Viniegra; Victor Javier Sánchez-Arevalo Lobo; Santiago Ramón y Cajal; Ricardo Sánchez-Prieto
Journal:  Oncogene       Date:  2003-06-26       Impact factor: 9.867

Review 2.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

3.  The search for physiological substrates of MAP and SAP kinases in mammalian cells.

Authors:  P Cohen
Journal:  Trends Cell Biol       Date:  1997-09       Impact factor: 20.808

4.  Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest.

Authors:  K Takenaka; T Moriguchi; E Nishida
Journal:  Science       Date:  1998-04-24       Impact factor: 47.728

Review 5.  Protein kinase cascades activated by stress and inflammatory cytokines.

Authors:  J M Kyriakis; J Avruch
Journal:  Bioessays       Date:  1996-07       Impact factor: 4.345

6.  ASK1-P38 pathway is important for anoikis induced by microtubule-targeting aryl chloroethylureas.

Authors:  Jessica Fortin; Alexandre Patenaude; Réna G Deschesnes; Marie-France Côté; Eric Petitclerc; René C-Gaudreault
Journal:  J Pharm Pharm Sci       Date:  2010       Impact factor: 2.327

7.  Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors.

Authors:  L C Mahadevan; A C Willis; M J Barratt
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

8.  Cytokine activation of p38 mitogen-activated protein kinase and apoptosis is opposed by alpha-4 targeting of protein phosphatase 2A for site-specific dephosphorylation of MEK3.

Authors:  Todd D Prickett; David L Brautigan
Journal:  Mol Cell Biol       Date:  2007-04-16       Impact factor: 4.272

Review 9.  Development of distamycin-related DNA binding anticancer drugs.

Authors:  S Marchini; M Broggini; C Sessa; M D'Incalci
Journal:  Expert Opin Investig Drugs       Date:  2001-09       Impact factor: 6.206

10.  Stress-activated mitogen-activated protein kinases c-Jun NH2-terminal kinase and p38 target Cdc25B for degradation.

Authors:  Sanae Uchida; Katsuji Yoshioka; Ryoichi Kizu; Hitoshi Nakagama; Tsukasa Matsunaga; Yukihito Ishizaka; Randy Y C Poon; Katsumi Yamashita
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.